PAYER PERSPECTIVES
Hepatitis C: New Treatments Emerge in 2014 That Will Have Profound Implications for Payers
Groundbreaking hepatitis C therapies represent a new era in treatment. But their cost is unprecedented, meaning health plans and PBMs are facing difficult formulary decisions.
Reflections on 2013—The First of the Breakthrough Therapies: A Payer Perspective
As the FDA expedites approval of novel therapies, plans will need strategies to provide appropriate access while remaining observant of potential adverse events.
The Changing Management of Prostate Cancer—Radium 223 Dichloride (Xofigo) Targets Bone Metastases
Prostate cancer is the most common solid organ tumor in men. According to the American Cancer Society, in 2013: about 238,590 new cases of prostate cancer will be diagnosed in the United States; about 29,720 men will die of prostate cancer.
The Changing Management of Multiple Sclerosis—Dimethyl Fumarate (Tecfidera) for MS
Patients with relapsing-remitting multiple sclerosis experience an accumulation of central nervous system damage and associated cognitive and physical disability progression. With the widespread use of disease modifying therapies, health plans have experienced improved clinical outcomes for MS together with increasing associated pharmacy-related expenses.
Managing Multiple Myeloma—Pomalidomide for Relapsed or Refractory Disease
On February 8, 2013, the US Food and Drug Administration approved pomalidomide (Pomalyst) for the treatment of patients with multiple myeloma who have received at least 2 previous myeloma therapies, including lenalidomide and bortezomib, but whose disease progressed while receiving these therapies or within 60 days of stopping the last therapy.
The Growing Cost of Specialty Pharmacy—Is it Sustainable?
We only have to take a brief look back to see that 10 years ago, most specialty drugs were injectable agents used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and growth disorders. Today, the list of agents that is considered specialty includes many oral drugs and even some inhaled agents. In just more than 2 decades, the specialty drug market place has grown substantially.
Tofacitinib: The First Oral Janus Kinase Inhibitor for Rheumatoid Arthritis
The US Food and Drug Administration approval of tofacitinib (Xeljanz) in November 2012 represents a potential for significant change in the approach to the treatment of rheumatoid arthritis.